title: A 1-year comparison of the efficacy and clinical tolerance in postmenopausal women of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone.
abstract: This double-blind, randomized, multi-center study compared the efficacy and clinical tolerance of a combined formulation containing 2 mg estradiol (E2) and 0.5 mg trimegestone (TMG) with a standard hormone replacement therapy containing estradiol valerate (E2V) and norgestrel (NG) in the treatment of climacteric symptoms. The study was conducted over 13 cycles, each of 28 days, and involved 634 subjects, of whom 481 completed the study. The primary efficacy variable was the percentage of subjects who showed at least a 50% reduction from baseline in the mean daily number of hot flushes in cycle 3. This was observed in 98.5% of the subjects in the E2 + TMG group and 93.3% of the subjects in the E2V + NG group (95% confidence interval of the difference, -8.6, -1.9). Significant differences in favor of the E2 + TMG combination were observed in the reduction in the mean daily number and severity of hot flushes, and in the percentage of subjects who had hot flushes at baseline but no hot flushes during treatment. There were no significant differences between the treatments in the Kupperman index and in urogenital signs or symptoms. Treatment with the E2 + TMG combination was well tolerated and the incidences of adverse events were similar in the two treatment groups. Breast pain was the main adverse event, possibly related to treatment that resulted in discontinuation. The mean number of bleeding days per cycle was significantly lower with the E2 + TMG combination than with the E2V + NG combination. The incidences of endometrial hyperplasia were low and comparable in both treatment groups. It was concluded that the E2 + TMG combination was either equivalent or superior to the E2V + NG combination in the treatment of hot flushes and other climacteric symptoms, and that its bleeding profile was favorable.
authors.affiliation: Diagnostisch Centrum, Eindhoven, The Netherlands.
authors.forename: J H
authors.initials: JH
authors.lastname: Meuwissen
authors.forename: L
authors.initials: L
authors.lastname: Beijers-De Bie
authors.forename: T
authors.initials: T
authors.lastname: Vihtamaki
authors.forename: R
authors.initials: R
authors.lastname: Tuimala
authors.forename: N
authors.initials: N
authors.lastname: Siseles
authors.forename: C
authors.initials: C
authors.lastname: Magaril
authors.forename: H S
authors.initials: HS
authors.lastname: The
authors.forename: P W
authors.initials: PW
authors.lastname: Houben
authors.forename: M
authors.initials: M
authors.lastname: Murga
authors.forename: D
authors.initials: D
authors.lastname: Spielmann
authors.forename: T J
authors.initials: TJ
authors.lastname: De Villiers
mesh_terms: D004311:Double-Blind Method; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D015914:Estrogen Replacement Therapy / Q000379:methods* / Q000592:standards; D005260:Female; D019584:Hot Flashes / Q000188:drug therapy; D006801:Humans; D008875:Middle Aged; D009644:Norgestrel / Q000008:administration & dosage* / Q000009:adverse effects; D017698:Postmenopause; D045167:Progesterone Congeners / Q000008:administration & dosage* / Q000009:adverse effects; D011397:Promegestone / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives; D018709:Statistics, Nonparametric
chemical_list: D004338:Drug Combinations; D045167:Progesterone Congeners; D009644:Norgestrel; C050319:trimegestone; D004958:Estradiol; D011397:Promegestone